Rayonier Advanced Materials (RYAM) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
5 Aug, 2026Executive summary
Strategic review of alternatives is progressing with urgency, aiming to maximize shareholder value, with a conclusion expected in Q4 2026.
Net sales for Q2 2026 increased 11% year-over-year to $376 million, driven by higher Cellulose Specialties pricing and increased sales volumes in Cellulose Commodities, Paperboard, and High Yield Pulp.
Loss from continuing operations improved to $33 million from $81 million in Q1, with adjusted EBITDA up to $40 million from $8 million sequentially and up 43% year-over-year.
Leadership transition to a new CEO with deep operational and transaction experience, focused on strengthening performance and supporting the review.
Emphasis on the differentiated Cellulose Specialties franchise, technical expertise, and strong customer relationships as core value drivers.
Financial highlights
Q2 2026 net sales reached $376 million, up 18% sequentially and 11% year-over-year.
Adjusted EBITDA for Q2 2026 was $40 million, up from $8 million in Q1 and $28 million in the prior-year quarter.
Net loss attributable to shareholders was $33 million in Q2 2026, compared to $363 million in Q2 2025.
Gross margin improved to $23 million in Q2 2026 from $(8) million in Q1 and was $24 million in the prior-year quarter.
Adjusted Free Cash Flow for the first half of 2026 was $(8) million, an improvement from $(65) million in the prior year period.
Outlook and guidance
Full-year outlook remains aligned with prior expectations for positive free cash flow in 2026.
Cellulose Specialties pricing expected to remain significantly above prior year levels through the second half; volumes to improve compared to the first half.
Paperboard market conditions are tightening, supporting a firmer pricing outlook.
Operational focus on reliability, productivity, and cost improvements to mitigate inflation and enhance cash generation.
Strategic review outcome and refinancing alternatives to be communicated in Q4.
Latest events from Rayonier Advanced Materials
- Q1 2026 posted $319M sales, $81M net loss, $8M EBITDA, and positive free cash flow.RYAM
Q1 2026 - Director nominee resigned; votes for this nominee won't count, all other matters unchanged.RYAM
Proxy filing - Board refresh, executive pay alignment, and governance reforms headline this year's proxy.RYAM
Proxy filing - Key votes include board declassification, supermajority removal, and executive pay approval.RYAM
Proxy filing - Board refresh, CEO change, and governance reforms highlight a focus on accountability and performance.RYAM
Proxy filing - 2026 targets positive cash flow, EBITDA growth, and new product launches amid disciplined execution.RYAM
Gabelli Funds Annual Specialty Chemicals Symposium - 2025 results showed lower revenue and EBITDA, with 2026 targeting free cash flow recovery.RYAM
Q4 2025 - Aiming to double EBITDA by 2027, leveraging price, cost, and biomaterials growth.RYAM
17th Annual Southwest IDEAS Conference - Q1 2025 net loss widened to $32M on lower sales and higher costs, but liquidity remains strong.RYAM
Q1 2025